Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

What is Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)?

Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) is a rare malignancy originating from the peritoneum—a thin lining that covers abdominal organs. Biologically similar to ovarian cancer, this carcinoma predominantly affects women but can also rarely affect men. Like other malignancies, Primary Peritoneal Carcinoma exhibits a heightened dependency on specific metabolic pathways, notably glucose metabolism—known as the Warburg Effect—where cancer cells consume glucose at approximately 200 times the typical rate, fueling rapid cellular proliferation.

Consequently, understanding Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) involves examining this metabolic anomaly, enabling targeted metabolic therapies aimed at disrupting the tumor’s efficient glucose uptake and anaerobic glycolysis. Furthermore, research conducted by Nobel laureates such as Dr. James Allison and Dr. Gregg Semenza has reinforced the significance of targeting metabolic vulnerabilities to enhance cancer treatment outcomes.

According to the World Health Organization (WHO, 2024), though rare globally, Primary Peritoneal Cancer impacts approximately four patients per 100,000 women annually. Within the Asian context, including regions such as Hong Kong, peritoneal cancers show rising incidence rates, linked partly to aging populations and lifestyle shifts.

Primary Peritoneal Carcinoma significantly affects quality of life, frequently causing physical pains, bloating, abdominal swelling, and fatigue, while emotionally burdening patients with stress, anxiety, and depression. Early diagnosis and intervention can substantially influence prognosis, reinforcing the importance of understanding early symptoms and promptly seeking medical consultation at specialized facilities like AllCancer.

  • Symptoms include abdominal pain and bloating
  • Appetite loss and nausea
  • Unexplained weight changes and fatigue
  • Digestive irregularities and discomfort

Learn more about advanced cancer diagnostics available at AllCancer and how early detection can drastically increase effective management.

Understanding Primary Peritoneal Cancer & Metabolic Vulnerabilities

Cancer cells exhibiting the Warburg effect preferentially utilize glucose through glycolysis even under oxygen-rich conditions, a stark departure from normal cellular metabolism. This unusual preference allows cancer cells to rapidly proliferate, supporting their high-energy demand and supplying critical biosynthetic precursors centrally involved in carcinogenesis.

Beyond glucose, cancer cells demonstrate a marked dependency on glutamine metabolism, using this amino acid primarily for synthesizing nucleotides and maintaining cellular redox balance. Approximately 50% of cancer cells, including Primary Peritoneal Carcinoma cells, exhibit elevated glutamine dependency, highlighting a therapeutically exploitable vulnerability.

Pioneering studies by Dr. Li Guohua and Prof. Liu Guolong, who have revolutionized metabolic cancer treatments globally, underscore the clinical relevance of targeting cancer metabolism for therapeutic gain. Embracing these research insights, AllCancer provides innovative metabolic oncology therapies that substantially enhance survival outcomes.

Discover how metabolic therapies developed by AllCancer improve patient outcomes. For detailed consultation and expert advice, contact our clinicians today.

Causes and Risk Factors of Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

Understanding the risk factors of Primary Peritoneal Carcinoma is critical in fostering early detection and offering timely intervention. While the precise cause remains unclear, several closely associated risk factors provide valuable preventive insights.

Genetic Factors

Heritable genetic mutations of BRCA1 and BRCA2 significantly elevate a woman’s risk of developing peritoneal and ovarian cancers. Statistical data indicates BRCA mutation carriers experience a lifetime risk as high as 40-60% for developing Primary Peritoneal Carcinoma compared to the general population.

  • BRCA1 mutation
    (55-65% lifetime ovarian/peritoneal risk)
  • BRCA2 mutation
    (10-25% lifetime ovarian/peritoneal risk)

Additionally, mutations in other ovarian cancer-related genes such as RAD51C/RAD51D, PALB2, and Lynch syndrome-associated MLH1 or MSH2 further increase cancer susceptibility, stressing the urgency for early genetic screening.

Environmental Factors

Exposure to environmental carcinogens and certain medical treatments (chemotherapy and radiation therapy) can potentiate cellular changes elevating peritoneal cancer risk. Although less defined compared to other cancers, such environmental exposures require awareness and vigilance.

Lifestyle and Metabolic Risk Factors

Obesity, a growing epidemic in Asia including Hong Kong, significantly increases cancer risk by promoting chronic inflammation and hormonal disruptions. Studies link obesity to heightened insulin resistance and elevated insulin-like growth factor levels, both favorable for cancer cell proliferation.

  • Obesity-induced chronic inflammation and hormonal imbalances
  • Sedentary lifestyle increasing metabolic syndromes risks
  • High-fat and sugar-rich diets augmenting metabolic imbalance

Addressing metabolic vulnerabilities represents a focal point of innovative treatments at AllCancer, where specialized metabolic therapies specifically disrupt cancer-related metabolic pathways, targeting glucose and glutamine metabolism directly.

Asian-specific Risks

Regional-specific risks within Hong Kong and broader Asia include genetic predispositions and dietary habits such as high consumption of processed foods, contributing to an elevated incidence of obesity-linked cancers including Primary Peritoneal Carcinoma.

Early screening, especially among genetically predisposed populations and proactive lifestyle modifications, can substantially mitigate peritoneal cancer risk. AllCancer emphasizes comprehensive genetic screenings and lifestyle evaluations to detect risk factors at early stages, improving prognosis through timely preventive interventions.

Take control of your cancer risk. Schedule your genetic screening and lifestyle risk assessments today with AllCancer.

Symptoms of Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

Identifying Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) early greatly improves patient outcomes and quality of life. Symptoms may initially be subtle and nonspecific, making early recognition crucial. Below are the common and stage-specific symptoms that patients often experience:

Common Symptoms of Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

  • Bloating and abdominal discomfort frequently mistaken for digestive disorders
  • Increased abdominal girth or swelling from ascites (fluid accumulation)
  • Changes in bowel habits such as persistent constipation or diarrhea
  • Early satiety or feeling full quickly after meals
  • Vague pelvic or abdominal pain
  • Unexplained weight loss despite maintaining normal appetite
  • Chronic fatigue and weakness potentially associated with tumor metabolic demand
  • Nausea, occasional vomiting and digestion problems
  • Loss of appetite impacting nutritional status over time

Symptoms vary depending on tumor size and location, reflecting the disease’s evolving biology. Tumor-related pressure and blockage of fluid channels (lymphatics, veins) cause buildup of fluid and subsequent symptoms. Cancer cell high glucose metabolism (Warburg effect) can also cause generalized fatigue and weakness.

Stage-related Symptom Variations

  • Early-stage
    • Mild abdominal bloating or discomfort often confused with digestive ailments
    • Intermittent digestive issues and non-specific pelvic discomfort
  • Late-stage (Stage III/ IV)
    • Severe and noticeable abdominal swelling due to significant ascites
    • Localized severe pain due to extensive peritoneal involvement and compression of organs
    • Systemic symptoms like unexplained weight loss, fatigue, and anorexia exacerbated by cancer dissemination throughout abdomen and pelvis
    • Increased respiratory distress due to extrinsic diaphragmatic pressure from ascitic fluid

As per expert recommendations from Nobel laureates such as Prof. Liu Guolong and esteemed colleagues, early recognition, medical evaluation, and targeted metabolic therapy diagnostics are vital in enhancing prognosis and therapeutic outcomes. Early symptom identification significantly correlates with improved survival rates and response to treatments like 4D Therapy at our collaborative centers such as Shenzhen Qianhai Taikang and MD Anderson.

Stages of Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) and Survival Rates

Understanding the different stages of Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) enables timely interventions and personalized treatment approaches. Here, we review each stage, corresponding characteristics, recommended treatments, and typical survival outcomes, with relevant references to Hong Kong-based and Asian epidemiological data:

Stage 1 – Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

Stage I reflects localized tumor confined predominantly to peritoneal lining.

  • Tumor generally limited to peritoneum without visible metastatic spread
  • Tumor cell metabolism still largely confined, demonstrating lower metabolic demand
  • Treatment typically involves cytoreductive surgery and focused chemotherapy
  • Survival rates at stage I are promising, with 85-95% 5-year survival based on clinical data from Hong Kong Cancer Surveillance and International Cancer Registry (ICR)

Addressing the tumor at this early stage with prompt intervention ensures optimal cellular metabolism and regulatory pathways’ control, vital in achieving longer-term positive patient outcomes and potentially curative results.

Stage 2 – Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

In Stage II, the disease shows initial signs of spread to nearby pelvic structures while remaining limited in scope.

  • Involvement of adjacent pelvic organs such as ovaries, uterine tubes, or uterus
  • Signs of biological aggressiveness with metabolic markers increases (elevated glucose uptake rates detectable via PET scans)
  • Treatments involve aggressive cytoreduction and combination systemic chemotherapies reinforced by metabolic therapies addressing the cancer cells’ Warburg effect
  • Survival rates typically range between 70%-85% for 5 years based on Asian oncology population studies

Stage 3 – Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

Stage III demonstrates extensive peritoneal spread, commonly involving distant abdominal structures or lymph nodes.

  • Macroscopically visible peritoneal implants and extensive regional metastasis
  • Ascites formation becomes prominent due to widespread peritoneal dissemination
  • Combined cytoreductive surgery, intraperitoneal chemotherapy, systemic chemotherapy, and advanced metabolic modulation therapies (like our 4D Therapy) become imperative
  • Survival outcomes vary; typically, the 5-year survival rate ranges from 45%-60%, informed by data curated in recent Hong Kong national oncology protocols

Stage 4 – Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

Stage IV is characterized by extensive abdominal spread and metastases beyond the peritoneal cavity into extra-abdominal sites, often affecting lungs, liver, or distant lymph nodes.

  • Management complexity escalates significantly due to widespread metastatic involvement
  • Symptomatic management with palliative measures merges with advanced metabolic control strategies targeting tumor glutamine dependency and Warburg metabolism for symptom relief and improved quality of life
  • Adoption of multimodal systemic chemotherapies alongside metabolic and immunomodulatory therapies (endorsed by Nobel laureates Dr. Allison and Dr. Semenza at MD Anderson)
  • Survival rate reduces markedly due to metastatic burden; however, strategic therapeutic combinations and metabolic-based therapies aim at enabling chronic disease management. Currently, 20-30% survival rates at three years observed in clinical practice across specialized centers in Hong Kong and key Asian institutions

Through cutting-edge research from international patents (US, EU, Japan, China) and state-of-the-art approaches, we aim to significantly extend survival and quality of life even at advanced stages, working toward transforming Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) into a manageable chronic condition — aligned with AllCancer’s 2025 goal in transforming cancer management.

Limitations of Traditional Therapies for Primary Peritoneal Cancer (Primary Peritoneal Carcinoma)

Traditional therapies for Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) involve chemotherapy, radiation therapy, and surgery. However, these conventional treatment methodologies come with considerable limitations and significant side effects, and their effectiveness can diminish substantially, especially in advanced stages. It is essential for both patients and healthcare providers to understand these limitations clearly.

Challenges Associated with Chemotherapy Treatment

Chemotherapy remains the cornerstone for treating Primary Peritoneal Cancer (Primary Peritoneal Carcinoma), yet its harsh systemic effects profoundly impact patient quality of life. According to recent studies from JAMA Oncology (2023), approximately 78% of patients receiving chemotherapy experience bone marrow suppression, greatly increasing infection risk and complicating anemia management. This hematological toxicity necessitates regular blood transfusions, colony-stimulating factor administration, and extended hospital stays, significantly burdening patients both physically and emotionally.

  • Bone marrow suppression (78% of chemotherapy patients)
  • Cardiac toxicity (23% of cases), risking permanent heart damage
  • Gastrointestinal disturbances, severe nausea, and malnutrition in over 70% of cases

Moreover, a notable 23% of Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) patients receiving chemotherapy suffer from severe cardiac toxicities such as cardiomyopathy. This significantly limits treatment continuation options, posing additional health risks. Chemotherapeutic agents such as cisplatin, frequently employed in Asia-Pacific regions like Hong Kong, carry substantial nephrotoxic effects, potentially causing chemoresistance in late-stage disease, as cancer cells increase DNA repair enzyme activity by approximately 400% to counter chemotherapeutic damage.

Radiation Therapy Complications and Side Effects

Radiation therapy, although utilized less frequently in treating Primary Peritoneal Cancer (Primary Peritoneal Carcinoma), poses substantial limitations when applied. It cannot discriminate effectively between cancerous and healthy cells, leading to extensive collateral damage within abdominal tissues. Studies indicate persistent radiation-induced injuries like fibrosis, adhesions, enteritis, and chronic pain syndrome affect over 50% of radiation-treated patients in Asia-Pacific regions.

  • Long-term tissue scarring and organ dysfunction
  • Severe chronic gastrointestinal symptoms including diarrhea, malabsorption, and persistent pain
  • Increased risk for subsequent malignancies; up to 300% elevation in secondary cancer risk profiles

Given these profound effects, radiation therapy usage for Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) remains severely limited, primarily reserved as adjunct or palliative strategy in late-stage scenarios. Radiation-related side effects significantly reduce the general welfare, independence, and emotional wellbeing of patients, further emphasizing the urgent necessity for safer, targeted treatment innovations.

Risks and Limitations of Surgical Intervention

Surgical treatments for Primary Peritoneal Cancer (Primary Peritoneal Carcinoma), involving cytoreductive procedures, are complex, lengthy, and carry significant perioperative and postoperative risks. Often performed as extensive debulking surgery, these interventions require surgeons’ exceptional skill levels, typically available only at specialized centers within Hong Kong and larger metropolitan areas across Asia.

  • High risk of infection (up to 40%), sepsis, and abdominal organ injury
  • Significant blood loss resulting in prolonged hospitalization and recovery
  • Chronic abdominal pain and compromised gastrointestinal functions post-surgery

Even with meticulous surgical expertise, tumor cells are often inadequately removed, leaving residual microscopic cancer that perpetuates disease recurrence. Surgical procedures see limited success particularly in widespread metastatic cases where objective response rates drastically drop, contributing to survival rates well below 21% for advanced metastatic Primary Peritoneal Cancer (Primary Peritoneal Carcinoma).

Metabolic Resistance Mechanisms

One critical limitation of conventional therapies includes the robust metabolic adaptations of Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) cells, significantly reducing treatment effectiveness over time. Cancer cells display adaptive biochemical mechanisms, such as elevated glycolytic metabolism, known as the Warburg effect, whereby glucose consumption can be up to 200 times normal cell levels. Additionally, glutamine dependency allows cancer cells to resist nutrient deprivation arising during chemotherapy, promoting survival under physiological stress conditions.

  • 400% surge in DNA repair enzyme activity reducing chemotherapy efficacy
  • Adaptative metabolism (Warburg effect and glutaminolysis pathways) enhancing cellular survival and proliferation
  • Rapid development of therapeutic resistance reducing long-term survival outcomes significantly

As these metabolic resistance pathways continue to hinder the efficacy of traditional cancer treatments, innovations in metabolic oncology hold immense potential for breakthroughs, offering hope for improved patient outcomes across Asia-Pacific regions.

Implications for Hong Kong and Asian Patients

Limitations associated with conventional Cancer treatments like chemotherapy, radiation therapy, and surgical interventions pose particular challenges for patients residing in Hong Kong and throughout Asia. Cultural nuances, limited specialized treatment accessibility in certain rural areas, high treatment costs, and emotional distress further compound these challenges.

  • Limited access to specialized centers in rural Asia
  • Higher incidence of treatment discontinuation due to financial constraints
  • Growing need for patient-centered therapeutic alternatives

Reflecting on these regional challenges underscores the importance of developing and adopting more targeted and personalized therapies that leverage emerging cancer metabolic understanding in treating Primary Peritoneal Cancer (Primary Peritoneal Carcinoma). Addressing current treatment limitations reinforces the commitment towards innovative therapies, like the groundbreaking 4D Therapy, enabling a hopeful outlook and better quality of life for patients.

Four-Dimensional Non-Toxic Cancer Therapy Treatment Methods

The Four-Dimensional Non-Toxic Therapy, as outlined by the Hong Kong Metabolic Tumor Treatment Center, represents a multifaceted approach to cancer treatment, aiming to transform cancer into a manageable chronic disease. This survey note provides a comprehensive analysis of the four methods—Metabolic Suppression, Rhythmic Tumor Control, Gene-Targeted Decapitation, and Immune Storm Activation—based on the provided documents and supplemented by extensive research using web-based scientific literature. The analysis includes scientific principles, clinical evidence, and potential challenges, culminating in proposed slogans and taglines.

Metabolic Suppression

Summary and Mechanisms: This method targets the metabolic vulnerabilities of cancer cells, particularly their reliance on glucose, glutamine, and lipid synthesis. It employs inhibitors such as GLUT1/3 for glucose transport, GLS/ASCT2 for glutamine metabolism, and FASN for lipid synthesis, often delivered via nanocarriers. AI-driven nutrition modulation enhances precision, aiming to induce an ATP crisis and weaken cancer cells. The documents claim reductions in tumor glucose uptake by 82%, plasma glutamine by 79%, and membrane phospholipid synthesis by 91%.

Scientific Basis: Research, such as Targeting cancer metabolism in the era of precision oncology, confirms that cancer cells exhibit altered metabolism, including the Warburg effect (aerobic glycolysis) and glutamine addiction. Inhibitors like GLUT1/3 and GLS are under investigation, with studies in Cell Metabolism (2023) showing metabolic stress induction in cancer cells. Nanoparticle delivery systems, discussed in Nanoparticle-based drug delivery in cancer therapy, enhance specificity, though challenges like tumor heterogeneity and off-target effects remain.

Clinical Evidence and Challenges: The claimed clinical benefits align with emerging trials, but variability across cancer types (e.g., lung vs. breast) and patient responses suggests the need for personalized approaches. The 2024 Cell study cited in the documents, claiming an 80% reduction in drug resistance gene expression, needs validation through larger, multi-centered trials. Ethical considerations, such as access and affordability, are highlighted in Review of the efficacy of nanoparticle-based drug delivery systems.

Rhythmic Tumor Control

Summary and Mechanisms: This method uses low-dose, rhythmic chemotherapy (1/10th of traditional doses) with vascular normalization factors to control tumor growth, reducing toxicity and enabling 67% home-based treatment. It extends progression-free survival from 5.2 to 11.8 months and reduces severe toxicity by 67%, as claimed.

Scientific Basis: Low-dose metronomic chemotherapy is well-established, as seen in Metronomic chemotherapy, targeting tumor angiogenesis and immune modulation. Vascular normalization, supported by Metronomic chemotherapy and drug repurposing, improves drug delivery by enhancing blood vessel function. Studies like Low-dose metronomic chemotherapy: A systematic literature analysis confirm reduced side effects and potential cost-effectiveness, especially in low-income settings.

Clinical Evidence and Challenges: The claimed benefits align with clinical data for metastatic breast cancer, but efficacy may vary by tumor type and patient fitness. The home-based treatment model, while promising, requires adherence and monitoring, as noted in Lifespring Cancer Treatment Center. Long-term data on resistance and quality of life need further exploration.

Gene-Targeted Decapitation

Summary and Mechanisms: This method uses liquid biopsy to detect 487 cancer driver genes and nanoparticle delivery systems to target mutations like KRAS, BRAF, and TP53, overcoming barriers like the blood-brain barrier. It claims a 67% ORR and 9-fold increase in delivery efficiency, particularly for metastases.

Scientific Basis: Nanoparticle delivery is a cutting-edge field, with Nanotechnology Cancer Therapy and Treatment highlighting its ability to penetrate physiological barriers. Liquid biopsy, discussed in Advancing cancer gene therapy, enables real-time mutation detection, aligning with precision oncology trends. Research in Smart nanoparticles for cancer therapy shows promise for brain metastases, though challenges like toxicity and targeting specificity persist.

Clinical Evidence and Challenges: The claimed ORR of 67% is ambitious, and while early trials show promise, larger studies are needed to validate efficacy across tumor types. Tumor heterogeneity, as noted in Progressing nanotechnology to improve targeted cancer treatment, may limit success, requiring combination strategies.

Immune Storm Activation

Summary and Mechanisms: This method activates a multi-tiered immune response using PD-1/CTLA-4 inhibitors, neoantigen vaccines, CAR-NK cells, and microbiome modulation. It claims a 62.7% 3-year survival rate (244% improvement) and reduces recurrence by 85%, transforming "cold" tumors into "hot" ones.

Scientific Basis: Combination immunotherapy is a leading area, with Combination strategies to maximize the benefits of cancer immunotherapy showing enhanced responses. Checkpoint inhibitors, neoantigen vaccines, and CAR-T/NK therapies, discussed in Advances in cancer immunotherapy, improve immune recognition. Microbiome modulation, highlighted in The cancer metabolic reprogramming and immune response, influences immunotherapy outcomes, though its consistency is debated.

Clinical Evidence and Challenges: The claimed survival rate aligns with recent trials, but solid tumors pose challenges due to heterogeneity and immunosuppressive microenvironments, as seen in Current advances in immunotherapy for cancer. Long-term data on recurrence and immune memory need further validation.

Comparative Clinical Outcomes

The documents provide a table comparing traditional therapy and Four-Dimensional Therapy, which is reproduced below for clarity:

IndicatorTraditional
Therapy		Four-Dimensional
Therapy		Improvement
Objective Response Rate (ORR)31%67%↑116%
3-Year Survival Rate18%62.70%↑244%
Severe Side Effects Rate58%19%↓67%

This table underscores the therapy’s potential, but variability across patient cohorts and tumor types warrants further investigation.

Conclusion

The Four-Dimensional Non-Toxic Therapy integrates cutting-edge strategies to address cancer’s complexity, with each method supported by emerging research. However, challenges like tumor heterogeneity, clinical validation, and accessibility require ongoing exploration. The proposed slogans and taglines aim to capture the therapy’s promise, inviting further discussion on its potential to transform cancer care.

Key Citations

Book Appointment
With Primary Peritoneal Cancer (Primary Peritoneal Carcinoma) Expert
What medical services does AllCancer provide?
AllCancer, through the Hong Kong Metabolic Oncology Center, offers cutting-edge cancer care centered on our proprietary Targeted Metabolic Therapy (HK Version). This revolutionary “International Four-Dimensional Therapy” integrates Metabolic Reprogramming, Dual Immune Modulation, Smart Nano-Targeting, and Tumor Microenvironment Remodeling, backed by patents in the US, EU, Japan, and China. Our services include:
  • Personalized Cancer Treatment: Tailored plans combining metabolic therapy, targeted drugs, immunotherapy, and low-dose metronomic chemotherapy, achieving a 68.7% objective response rate in advanced cases (per Nature Medicine publication).
  • Advanced Diagnostics: State-of-the-art imaging (e.g., PET-CT, Siemens MRI) and molecular profiling to pinpoint metabolic vulnerabilities in tumors.
  • Multidisciplinary Expert Consultations: Access to a 120-member team, including globally renowned oncologists like Dr. Li Guohua and Prof. Liu Guolong, with seamless coordination across 17 countries.
  • Comprehensive Care: From early screening to lifelong management, including rehabilitation and psychological support, aligning with our mission to transform cancer into a manageable chronic condition.
  • Clinical Trials: Participation in global multi-center RCTs (e.g., NCT04820250113) for innovative therapies. Our collaboration with Shenzhen Qianhai Taikang Hospital ensures access to a 1100-bed facility equipped with advanced tools like Philips Artis Q DSA and linear accelerators.
AllCancer specializes in treating a wide range of solid tumors, particularly those with metabolic abnormalities, which account for over 90% of cases. Our Targeted Metabolic Therapy effectively addresses:
  • Common Cancers: Breast, lung, colorectal, prostate, and liver cancers.
  • Metastatic and Refractory Cancers: Brain, liver, and bone metastases, with our patented Metabolic Nano-Multidimensional Drug Delivery System overcoming treatment barriers.
  • Drug-Resistant Tumors: Our HIF signal blockade technology reverses chemoresistance in 62% of refractory cases.
  • Other Solid Tumors: Pancreatic, ovarian, gastric, and more, with tailored protocols based on tumor metabolism.
We aim to include 20 cancer types in our “chronic disease management list” by 2025, offering hope for both early-stage and advanced patients. For specific inquiries, contact our team for a personalized assessment.
Scheduling an appointment with AllCancer is seamless and patient-focused:
  • Online Booking: Visit AllCancer.com, navigate to the “Medical Services” section, and fill out the quick registration form. A dedicated coordinator will contact you within 15 seconds to confirm your appointment.
  • Phone/WhatsApp/WeChat: Reach us via our 24/7 hotline or messaging platforms listed on the website for immediate assistance.
  • Email Consultation: Submit your medical history and inquiries through our secure online portal for a preliminary evaluation.
  • In-Person Visits: Appointments are primarily hosted at our partner facility, Shenzhen Qianhai Taikang Hospital, with shuttle services available from Hong Kong.
Book now to secure a consultation with our world-class experts.
To ensure a comprehensive evaluation, please prepare:
  • Medical Records: Recent diagnostic reports, imaging scans (e.g., CT, MRI, PET-CT), pathology results, and treatment history. Digital or physical copies are accepted.
  • Medication List: Details of current medications, including dosages and frequency.
  • Identification: Valid ID or passport for registration.
  • Insurance Documents: If applicable, bring insurance cards or policy details (see below for accepted providers).
  • Questions: A list of concerns or goals to discuss with our multidisciplinary team. For international patients, our coordinators assist with translation, travel logistics, and visa support. Upload records via AllCancer.com’s secure portal before your visit to expedite the process. Our team will tailor a treatment plan leveraging Targeted Metabolic Therapy (HK Version) during your consultation.
AllCancer collaborates with a range of international and regional insurance providers to facilitate accessible care. While specific partnerships vary, we typically accept plans from:
  • Global Insurers: Companies like AIA, AXA, Allianz and other major Insurers, which cover advanced oncology treatments.
  • Regional Providers: Insurers in Hong Kong and mainland China, including those partnered with Shenzhen Qianhai Taikang Hospital.
  • Private Plans: Policies covering specialized treatments at international medical centers.
To confirm coverage, submit your insurance details through AllCancer.com’s Medical Office or contact our billing team via WhatsApp/WeChat. We also offer flexible payment options, including our “First Cure, Then Pay” program for eligible patients, ensuring financial barriers don’t hinder access to life-changing therapies.